BETHESDA, Md., April 26 Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its first quarter 2010 results on Wednesday, May 5, 2010, at 8:30 AM ET.
To participate in the conference call, please dial 866-783-2138 (domestic) or 857-350-1597 (international) and reference the access code 84140824. The presentation will be available via webcast at:
A replay of the call will be available from 11:30 AM ET on May 5, 2010 until midnight on June 5, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 49266743. The archived webcast will be available for 30 days in the Investor Relations section of the Micromet website at www.micromet-inc.com.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com
SOURCE Micromet, Inc.